Hims & Hers Health Inc (NYSE:HIMS) reported financial results for the first quarter on Monday after the bell. Here’s a look at the key details from the print.
Q1 Earnings: Hims & Hers Health reported first-quarter revenue of $586.01 million, beating estimates of $538.2 million, according to Benzinga Pro. The company reported first-quarter earnings of 20 cents per share, beating analyst estimates of 12 cents per share.
Total revenue was up 111% on a year-over-year basis as subscribers grew to 2.4 million in the quarter, up 38% year-over-year. Gross margin came in at 73% in the first quarter. The company reported operating cash flow of $109.1 million and free cash flow of $50.1 million in the quarter.
“We’re starting 2025 with incredible momentum. Millions of people are turning to us for access to care that is personal, affordable, and has the potential to drive better outcomes,” said Andrew Dudum, co-founder and CEO of Hims & Hers Health.
“We’re building a platform that puts the individual at the center of every decision and others are taking notice. Over time, we expect wider collaboration across the industry, inclusive of pharmaceutical players, innovative leaders in diagnostic and preventative testing, and world-class providers.”
Guidance: Hims & Hers Health guided for second-quarter revenue of $530 million to $550 million versus estimates of $564.56 million.
The company continues to expect full-year 2025 revenue to be in the range of $2.3 billion to $2.4 billion versus estimates of $2.32 billion, according to Benzinga Pro.
Hims & Hers Health also provided a longer-term outlook, laying out expectations for at least $6.5 billion in annual revenue for full-year 2030, and adjusted EBITDA of at least $1.3 billion.
Hims & Hers executives will hold a conference call at 5 p.m. ET to further discuss the company’s quarterly performance.
HIMS Price Action: Hims & Hers Health shares were down 1.03% at $41.45 in Monday’s after-hours session at publication time, according to Benzinga Pro.
Read Next:
Photo: Lori Butcher/Shutterstock.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。